These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23127721)

  • 61. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease.
    Palmer SM; Robinson LJ; Wang A; Gossage JR; Bashore T; Tapson VF
    Chest; 1998 Jan; 113(1):237-40. PubMed ID: 9440597
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inhaled areosolized prostacyclin and pulmonary hypertension during anesthesia for lung transplantation.
    Della Rocca G; Coccia C; Costa MG; Pompei L; Di Marco P; Vizza CD; Venuta F; Rendina EA; Pietropaoli P; Cortesini R
    Transplant Proc; 2001; 33(1-2):1634-6. PubMed ID: 11267451
    [No Abstract]   [Full Text] [Related]  

  • 63. Acute pulmonary edema caused by epoprostenol infusion in a child with scimitar syndrome and pulmonary hypertension.
    von Schnakenburg C; Peuster M; Norozi K; Roebl M; Maibohm M; Wessel A; Fink C
    Pediatr Crit Care Med; 2003 Jan; 4(1):111-4. PubMed ID: 12656556
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Development of nonspecific interstitial pneumonitis associated with long-term treatment of primary pulmonary hypertension with prostacyclin.
    Kesten S; Dainauskas J; McLaughlin V; Rich S
    Chest; 1999 Aug; 116(2):566-9. PubMed ID: 10453891
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hypocalcemia after Denosumab in a Pulmonary Hypertension Patient Receiving Epoprostenol.
    De Muynck B; Leys M; Cuypers J; Vanderschueren D; Delcroix M; Belge C
    Respiration; 2018; 95(2):139-142. PubMed ID: 29485420
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The globalization of clinical trials in pulmonary arterial hypertension.
    Park MH; Rubin LJ
    J Heart Lung Transplant; 2010 Feb; 29(2):157-8. PubMed ID: 20113908
    [No Abstract]   [Full Text] [Related]  

  • 67. Comparative analysis of Micrococcus luteus isolates from blood cultures of patients with pulmonary hypertension receiving epoprostenol continuous infusion.
    Hirata Y; Sata M; Makiuchi Y; Morikane K; Wada A; Okabe N; Tomoike H
    J Infect Chemother; 2009 Dec; 15(6):424-5. PubMed ID: 20012737
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Micrococcus blood stream infection in patients receiving epoprostenol].
    Mitsutake K; Nogami T
    Kansenshogaku Zasshi; 2005 Oct; 79(10):829-30. PubMed ID: 16296331
    [No Abstract]   [Full Text] [Related]  

  • 69. Effect of Weight on Parenteral Prostacyclin Analogues Dosing in Pulmonary Hypertension.
    Raeisi-Giglou P; Wang XF; Dakkak W; Bair N; Dweik RA; Tonelli AR
    Chest; 2017 May; 151(5):1189-1192. PubMed ID: 28483121
    [No Abstract]   [Full Text] [Related]  

  • 70. Pulmonary Edema Following Initiation of Parenteral Prostacyclin Therapy for Pulmonary Arterial Hypertension: A Retrospective Study.
    Khan NA; Khan RA; Tonelli AR; Highland KB; Chaisson NF; Jacob M; Renapurkar R; Dweik RA; Heresi GA
    Chest; 2019 Jul; 156(1):45-52. PubMed ID: 30776364
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Epoprostenol for the treatment of pulmonary arterial hypertension.
    Cristo Ropero MJ; Cruz-Utrilla A; Escribano-Subias MP
    Expert Rev Clin Pharmacol; 2021 Aug; 14(8):1005-1013. PubMed ID: 34030557
    [No Abstract]   [Full Text] [Related]  

  • 72. Clinical Complications with the Delivery of Inhaled Epoprostenol in the Operating Room.
    Bhatt AM; Stein EJ
    Anesthesiology; 2017 Aug; 127(2):383. PubMed ID: 28323647
    [No Abstract]   [Full Text] [Related]  

  • 73. Subclinical venous access infection and clinical worsening in pulmonary arterial hypertension.
    Chebib N; Mornex JF; Cottin V
    J Heart Lung Transplant; 2017 Mar; 36(3):369-370. PubMed ID: 27914895
    [No Abstract]   [Full Text] [Related]  

  • 74. Severe erythroderma as a complication of continuous epoprostenol therapy.
    Ahearn GS; Selim MA; Tapson VF
    Chest; 2002 Jul; 122(1):378-80. PubMed ID: 12114387
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prostacyclin in primary pulmonary hypertension.
    Magnani B; Galiè N
    Eur Heart J; 1996 Jan; 17(1):18-24. PubMed ID: 8682125
    [No Abstract]   [Full Text] [Related]  

  • 76. Indwelling central venous catheter occlusion during chronic epoprostenol infusion.
    Kopeć G; Waligóra M; Stępniewski J; Podolec P
    J Heart Lung Transplant; 2018 Jul; 37(7):938-940. PubMed ID: 29731239
    [No Abstract]   [Full Text] [Related]  

  • 77. Epoprostenol therapy as a bridge to pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension.
    Kerr KM; Rubin LJ
    Chest; 2003 Feb; 123(2):319-20. PubMed ID: 12576339
    [No Abstract]   [Full Text] [Related]  

  • 78. The "Flolan Rash": An Impressively Asymptomatic and Non-Inflammatory Eruption Following Long-Term Epoprostenol Therapy.
    Hutchison D; Juhasz M; Smith J; Lee B
    J Drugs Dermatol; 2022 Nov; 21(11):1249-1251. PubMed ID: 36342724
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Giant Fold Gastritis Induced by Epoprostenol Infusion in Patients With Pulmonary Arterial Hypertension.
    Miura Y; Kataoka M; Chiba T; Inami T; Yoshino H; Satoh T
    Circ J; 2018 Sep; 82(10):2676-2677. PubMed ID: 30135321
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Flolan infusion interruption: a lethal complication during venous access.
    Falk A; Lookstein RA; Mitty HA
    J Vasc Interv Radiol; 2001 May; 12(5):667-8. PubMed ID: 11340154
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.